CORPORATE ACCESS

A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.

Your Search Healthcare

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA™ Opportunity and Commercialization Plan

Jun 9, 2025

Gross proceeds from offering total $16.6 million.Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and...

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

Jun 6, 2025

Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused...

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA™ (gepirone) Extended-Release Tablets in the United States

Jun 6, 2025

Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.EXXUA has demonstrated significant improvement in depression symptoms in...

Precision Optics Expands Facilities to Meet Growing Backlog

Jun 5, 2025

Company signs lease to move corporate offices and engineering development to Littleton, MA Move allows for expansion of production capabilities in Gardner, MA to meet increased backlog GARDNER, Mass. and LITTLETON, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Precision...

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

Jun 5, 2025

PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and...

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Jun 4, 2025

PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced that members of its executive leadership team will be attending and participating in the...

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

Jun 2, 2025

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyadic is well positioned to seize on geopolitical tailwinds driving...

Analyst Insights: Investing in MedTech

May 29, 2025

Adam Lowensteiner, Vice President of Lytham Partners sits down with Jeffrey Cohen of Ladenburg Thalmann & Co. for a timely discussion on the current state of the medtech sector, key growth drivers, and where investors should focus next. This Panel was recorded during...

ImmuCell Corp. (ICCC) Company Webcast

May 29, 2025

This webcast features ImmuCell Corporation (Nasdaq: ICCC). ImmuCell Corporation's purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. This company webcast was recorded during the Lytham...

Reviva Pharma (RVPH) Company Webcast

May 29, 2025

Reviva Pharmaceuticals Holdings (Nasdaq: RVPH) is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their...

INVO Fertility (IVF) Fireside Chat

May 29, 2025

This fireside chat features INVO Fertility. INVO Fertility (Nasdaq: IVF) is a healthcare services fertility company dedicated to expanding assisted reproductive technology (“ART”) care to patients in need. This fireside chat was recorded during the Lytham Partners...

Precision Optics (POCI) Company Webcast

May 29, 2025

Precision Optics Corporation (Nasdaq: POCI) is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new...

PolyPid (PYPD) Company Webcast

May 29, 2025

This webcast features PolyPid. PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. This company webcast was recorded during the Lytham Partners Spring 2025 Investor Conference.

Scientific Industries (SCND) Company Webcast

May 29, 2025

Scientific Industries (OTCQB: SCND) is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the product name DOTS. This...

Aurora Spine (ASAPF / ASG) Fireside Chat

May 29, 2025

Aurora Spine Corporation (OTCQB: ASAPF / TSXV: ASG) is focused on bringing new solutions to the spinal implant and pain care markets through a series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. This fireside chat was...

NeurAxis (NRXS) Company Webcast

May 29, 2025

NeurAxis, Inc. (NYSE American: NRXS) is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. This company webcast was recorded during the Lytham Partners Spring 2025 Investor...

SBC Medical Group (SBC) Company Webcast

May 29, 2025

This webcast features SBC Medical Group Holdings. SBC (Nasdaq: SBC) owns and provides management services to cosmetic treatment centers mainly in Japan. This company webcast was recorded during the Lytham Partners Spring 2025 Investor Conference.

Unicycive Therapeutics (UNCY) Fireside Chat

May 29, 2025

For this presentation we welcome Unicycive Therapeutics. Unicycive Therapeutics (Nasdaq: UNCY) is a biotechnology company developing novel treatments for kidney diseases. This fireside chat was recorded during the Lytham Partners Spring 2025 Investor Conference.

Opus Genetics (IRD) Company Webcast

May 29, 2025

Opus Genetics (Nasdaq: IRD) is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and other treatments for ophthalmic disorders. This company webcast was recorded during the Lytham...

IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System

May 29, 2025

WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its...

INVO Fertility to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 27, 2025

SARASOTA, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of...

Precision Optics to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 27, 2025

GARDNER, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced it will...

NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 27, 2025

CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will...

NeurAxis Announces Closing of $5.0 Million Registered Direct Offering

May 22, 2025

Strengthens Balance Sheet and Provides Growth CapitalCARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and...

NeurAxis Announces $5.0 Million Registered Direct Offering

May 21, 2025

CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today...

INVO Fertility Announces First Quarter 2025 Financial Results

May 20, 2025

Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya TherapeuticsSARASOTA, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the...

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025

CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025

- 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment - - Full data set from RECOVER OLE highlighting clinical response, safety, efficacy, adherence, and...

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

May 15, 2025

PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel...

Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 14, 2025

Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant...

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

May 14, 2025

Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectivelyAdjusted EBITDA1 of $3.9 millionTotal net revenue of $18.5 million up 32% year-over-yearCompany to host conference call and webcast today, May 14, 2025, at 4:30 p.m....

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

May 14, 2025

PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and...

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025

CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

May 12, 2025

Conference Call Scheduled for Thursday, May 15, 2025 at 9:00 AM ETPORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets...

NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

May 12, 2025

Conference call will be held today, Monday, May 12 at 9:00 am ETCARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and...

Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

May 8, 2025

GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has...

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025

Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE: ABT) validates the need for new anticoagulation...

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

May 7, 2025

DENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its third quarter of fiscal 2025,...

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

May 6, 2025

WOBURN, MA / ACCESS Newswire / May 6, 2025 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three months...

NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

May 5, 2025

Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern TimeCARMEL, Ind., May 05, 2025 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing...

IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

May 5, 2025

Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports...

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

May 1, 2025

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and...

INVO Fertility Announces 2024 Financial Results with 116% Annual Revenue Growth and Further Improvements in Adjusted EBITDA

Apr 30, 2025

SARASOTA, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of...

Reviva to Participate in the Citizens Life Sciences Conference

Apr 29, 2025

CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...

CORRECTION — IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

Apr 28, 2025

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead...

IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

Apr 28, 2025

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a...

INVO Fertility Confirms New Nasdaq Trading Symbol of “IVF”

Apr 24, 2025

SARASOTA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: NAYA), formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and...

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

Apr 24, 2025

CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Apr 21, 2025

Company to conduct 1x1 meetings on April 24, 2025 DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that it will be...

Precision Optics to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Apr 21, 2025

Company to conduct 1x1 meetings on April 24, 2025GARDNER, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries,...

« Older Entries

Next Entries »